Immutep Reports Positive Interim Phase I Data for Autoimmune Candidate IMP761
IMMP sits 32% above its 52-week low of $0.293 on light trading volume (0.1× avg).
Summary
Immutep announced positive interim Phase I data for its autoimmune candidate IMP761, showing favorable safety and statistically significant activity, providing a key positive development after recent clinical setbacks.
Key Events · Product Development and Regulatory · IMMP
-
Positive Phase I Results
IMP761 met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers during the single ascending dose part of the study.
-
Statistically Significant Activity
Phase I data showed statistically significant pharmacodynamic activity at 7 mg/kg, supporting further clinical investigation in autoimmune diseases.
-
Potential for Autoimmune Treatment
IMP761, a first-in-class LAG-3 agonist, demonstrated clear immunosuppressive effects, positioning it for multiple T-cell mediated autoimmune indications.
-
Strategic Importance
This positive development for a pipeline candidate in autoimmune diseases helps diversify the company's prospects following the recent discontinuation of its lead cancer trial.
Analysis · IMMP · Life Sciences
This filing provides crucial positive clinical data for IMP761, a LAG-3 agonist antibody for autoimmune diseases. The successful Phase I results, demonstrating favorable safety and statistically significant pharmacodynamic activity, offer a much-needed positive development for Immutep following the recent discontinuation of its lead cancer trial (TACTI-004). This data supports further clinical development and potential strategic partnerships, which are vital for the company's pipeline diversification and future.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMP was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.6M. The 52-week trading range was $0.29 to $3.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.